“I’d rather read a book than have sex with my husband,” Daphne sheepishly admitted during her last pap smear. She checked for my reaction. Would I brush off her complaint? Would I empathize? Better yet, could I offer any solutions?
Writer, Harvard-trained board-certified gynecologist, yoga teacher, mom. I believe in evidence-based ancient medicine. My specialty: bioidentical hormones + botanicals. I've partnered in, predicted, and personalized healing with women since 1989. For more info, visit www.SaraGottfriedMD.com. Return to balance, naturally™.
Friday, April 3, 2009
Low Libido? Natural Solutions
“I’d rather read a book than have sex with my husband,” Daphne sheepishly admitted during her last pap smear. She checked for my reaction. Would I brush off her complaint? Would I empathize? Better yet, could I offer any solutions?
Sunday, March 29, 2009
Testosterone: Satisfying Sex Once More per Month
Posted 01/16/2009
Robert A. Wild, MD, PhD, MPH
Author Information
Summary
Davis SR, Moreau M, Kroll R, et al, for the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008;359:2005-2017.
Therapy with a testosterone patch placed on the abdomen and delivering 300 µg daily provides some benefit to postmenopausal women with hypoactive sexual desire disorder (HSDD) who are not using estrogen therapy (ET) or estrogen plus progestin therapy (EPT), according to this randomized, double-blind, placebo-controlled study. The Phase III Research Study of Female Sexual Dysfunction of Women on Testosterone without Estrogen was initiated to determine the efficacy and safety of the testosterone patch in postmenopausal women not receiving estrogen who are suffering from HSDD and included women from 65 centers in the United States, Canada, Australia, the United Kingdom, and Sweden. The trial was conducted for 52 weeks and included 814 healthy postmenopausal women (aged 20-70 y) who were randomly assigned to receive a patch delivering either 150 µg or 300 µg testosterone per day or placebo. Participants were seen at baseline and at weeks 6, 12, 24, 36, and 52.
Efficacy was measured through women's responses on a weekly sexual activity log for 24 weeks and their scores on a Profile of Female Sexual Function and a Personal Distress Scale that were completed at baseline and at weeks 12 and 24. Adverse events were assessed at each visit through week 52. Some women continued treatment for a second year to provide additional safety data. The primary endpoint was a change through week 24 in frequency of satisfying sexual episodes over 4 weeks.
Baseline scores for frequency of satisfying sexual events, sexual desire, and distress were similar among groups. By week 24, the increase in 4-week frequency of satisfying events was significantly greater in the group with the 300 µg/day patch, with an increase of 2.1 episodes versus 0.7 episodes for placebo; P < 0.001. There was an increase in satisfying episodes of 1.2 in 4 weeks for the group receiving 150 µg testosterone. Both groups receiving testosterone had significantly increased scores for sexual desire and decreased scores for distress by week 24. The overall incidence of adverse events among groups was similar, with incidence of androgenic events highest in the 300-µg group, mainly increased hair growth. Breast cancer occurred in three women in the testosterone groups by week 52 and in an additional woman receiving hormone in the extension phase.
Commentary by Robert A. Wild, Md, Phd, Mph
Prior clinical trials (typically lasting 3-6 mo) with exogenous testosterone have been well conducted. The majority of trials show modest overall improvement in desire, sexual responsiveness, and frequency of orgasm as well as the number of satisfying sexual episodes (an endpoint required by the Food and Drug Administration [FDA] as evidence of efficacy). The short duration of these trials has worried those concerned about potential for serious adverse effects. Studies have been restricted to postmenopausal women taking ET or EPT.
Here, Davis et al assess testosterone therapy in postmenopausal women presumably estrogen deficient for up to 2 years. Efficacy was shown in women who had natural menopause but not in those with surgically induced menopause (probably because of a lack of statistical power). It is reasonable to ask whether the absolute increase of satisfying sexual episodes of 2.1 per month (1.4 more events per month than in the placebo group) was of value. The article does not indicate whether the women were asked if this was meaningful for them. Baseline data suggest it probably was. The mean number of such episodes almost doubled for the high-dose group (84% vs. 28% for placebo).
All groups had reaction at the application site (49.5%-52.8%, which is high) and various androgenic events (acne, alopecia, and voice deepening in less than 8% of each group). A little more than half in each group completed 52 weeks. Reasons for dropping out are well illustrated. Increased unwanted hair growth was significantly more common with 300 µg of testosterone per day (19.9% vs. 10.5% in the placebo group). Of greater concern are the four cases of breast cancer in the groups receiving testosterone, including one case detected 3 months after the extension period ended, versus zero in the placebo group. This could simply be due to chance, yet it is potentially worrisome and cannot be ignored. Findings suggest the need for caution until we understand more about testosterone's possible link with breast cancer and until we are better able to predict which patients are more likely to have negative effects.
Transdermal testosterone is available in Europe for use in surgically postmenopausal women who have persistent symptoms of HSDD despite adequate nonconjugated ET. However, the FDA in the United States is concerned about potential adverse effects over the long term. Breast cancer risk and potential detrimental lipoprotein physiology with unknown cardiovascular disease risk, as well as androgenic side effects (well documented here), have been the major challenges. The reported lipid profiling in this study is reassuring yet not definitive. Small, dense lipoprotein particle concentrations are a better predictor of events but were not measured. The pharmaceutical industry sponsored and analyzed this multisite study.
Because of a lack of FDA-approved testosterone patches in the United States for women, compounding pharmacy preparations for transdermal testosterone are often prescribed. If this route is chosen, full disclosure of off-label use and documentation of the known and unknown risks is strongly recommended. With the breast cancer concern and the need for studies with large numbers of women enrolled to answer this concern, it is likely that the FDA will continue to be very conservative regarding this issue.
From the NAMS First to Know e-newsletter released December 23, 2008
For more, please visit http://www.menopause.org/news.aspx
Friday, March 20, 2009
Libido: Bay Area Boosts

Libido is one of my favorite topics both as an area of physical, mental and spiritual inquiry and as a scholarly pursuit. Plus it's just fun to rev it up as much as possible especially when in a long-term monogamous relationship.
Now, as an aside, let me reassure my friends who are depleted and gave up caring about libido months or years ago: you can get your game back. My heart and pharmacoepia especially goes out to fellow depleted moms. That reminds me - I need to do a blog post on Depleted Mom Syndrome.
We are blessed in the Bay Area (and in New York and Los Angeles, and tell me if there are more libidinously enriching parts of our fine country) to have many places that offer succor to the libidinally-challenged.
My personal fave haunt is S Factor in San Fran, but also available in other cities. What is "S?" It's a hybrid form of movement that weaves yoga, pilates and connecting to your erotic creature. It's completely hot and a lot of fun. Take an intro class or sign up for a private with my dear friend, Michelle Cordero. Since I have a tendency to overachieve, I have attended 3 intros, devoured Sheila Kelly's book on "S" and practiced every DVD she's put out. My husband and I haven't figured out a way for me to attend a session in San Francisco - at two hours plus the commute time - it just doesn't fit into my schedule. But maybe your schedule? Get the intro schedule right here.
Here is Sheila teaching Oprah how to move.
Did you see the cover of last Sunday's NYT's Style Section with the orgasmic woman on the front page? So great. The article was about the Bay Area's OneTaste Urban Retreat Center, a co-ed gathering space with a focus on pleasing women. Where do I sign up? The founder, Nicole Daedone, is the creatrix of the joint, and at 41, she is tapping into a hugely unmet need among women -- the idea that we access freedom, full embodiment, and full-throttle living through our sexualty. A core of 38 men and women live in the SOMA location, but OneTaste offers workshops, a thriving online community (read: free), and a residential program. Check 'em out right here.
Wish it were always so easy....
For the rest of us, libido is a complex and very interdependent mix of the right hormonal balance (the players are estrogen, progesterone, testosterone, DHEA, cortisol among others) plus emotional connectivity, healthy body image, time and commitment. More on that later, in the meantime, enjoy your local resources and share via the comments section other discoveries for raising your libido.
Gottfried Center for Integrative Medicine's Fan Box
About Me
- Dr. Sara Gottfried, MD
- I'm an organic gynecologist, yoga teacher + writer. I earn a living partnering with women to get them vital and self-realized again. We're born that way, but often fall off the path. Let's take your lousy mood and fatigue, and transform it into something sacred and useful.


